12 Ways To Avoid Delays In Hemato-Oncology Trials
The COVID-19 pandemic has exacerbated the usual factors that can impact the start of clinical trials, including the need for the right study design, patient recruitment, appropriate inclusion/exclusion criteria, commercial/risk concerns and compliance with international regulatory constraints. While the world has waited anxiously for the industry to demonstrate an effective therapy for COVID-19, investors have shown caution in backing trials for other therapies given the delays and additional costs now associated with trials.
Our clinical operations team have pulled together useful ideas to reduce startup delays that they have gleaned from over 57 hematology-oncology trials with pediatric, adult and elderly populations.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.